Vimarsana
Biggest News Aggregation in the World

Page 3 - Scientific Interface News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Interface. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Interface Today - Breaking & Trending Today

An explorer in the sprawling universe of possible chemical combinations - Vimarsana News

An explorer in the sprawling universe of possible chemical combinations

MIT Associate Professor Heather Kulik is an explorer in the sprawling universe of possible chemical combination. The chemical engineer embraces computer models as “the only way to make a dent” in the vast number of potential materials that could solve important problems.

Source: mit.edu
An explorer in sprawling universe of possible chemical combinations - Vimarsana News

An explorer in sprawling universe of possible chemical combinations

The direct conversion of methane gas to liquid methanol at the site where it is extracted from the Earth holds enormous potential for addressing a

Why some melanoma patients do not respond to immunotherapy - Vimarsana News

Why some melanoma patients do not respond to immunotherapy

 E-Mail NEW YORK, NY (March 1, 2021)--By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients--across cancer types--do not respond, and in most cases, scientists are at a loss as to why. Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the tricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients a...

New screening platform leads to discovery of next-generation prodrugs for type 1 diabetes - Vimarsana News

New screening platform leads to discovery of next-generation prodrugs for type 1 diabetes

 E-Mail With nearly 2 million Americans battling type 1 diabetes, it is no surprise that clinical therapies for the disease are constantly evolving and improving. In type 1 diabetes mellitus, the body's immune system attacks and destroys insulin-producing β-cells. As a result, people living with type 1 diabetes lose insulin secretion and encounter difficulty regulating glucose levels -- especially after meals. Drugs developed to proliferate β-cells often are inefficient and have off-target effects that can dysregulate other cell types and pancreatic hormone production. To address these iss...